A Randomized, double-blind, placebo-controlled, multicenter phase III study of RAD001 Adjuvant Therapy in Poor Risk with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching PlaceboAfter Patients Have Achieved Complete Response with First-line Rituximab Chemotherapy
2020-07-04
عنوان الدراسة
A Randomized, double-blind, placebo-controlled, multicenter phase III study of RAD001 Adjuvant Therapy in Poor Risk with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching PlaceboAfter Patients Have Achieved Complete Response with First-line Rituximab Chemotherapy
داعم الدراسة
Novartis
دواء الدراسة
Everolimus
رقم بروتوكول الدراسة
CRAD001N2301
حالة الدراسة
Completed
موقع الدراسة
King Fahad Specialist Hospital (Dammam), King Abdulaziz Medical City NG (Riyadh), King Abdulaziz Medical City NG (Jeddah)
مرحلة الدراسة
3
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.